Brief: Fusen Pharmaceutical Receives NMPA Approval To Market Glucosamine Sulfate Capsule In PRC
17/04/2026 16:54
April 17 (Reuters) - Fusen Pharmaceutical Co Ltd 1652.HK: RECEIVES NMPA APPROVAL TO MARKET GLUCOSAMINE SULFATE CAPSULE IN PRC Further company coverage: 1652.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Fusen Pharmaceutical
See all newsBrief: Fusen Pharmaceutical Logs HY Loss Attributable RMB13.6 Million
Brief: Fusen Pharmaceutical Says Doxazosin Mesylate Extended-Release Tablets Approved For Marketing In China
Brief: Fusen Pharmaceutical Says Peramivir Injection First Neuraminidase Inhibitor Approved In China For Intravenous Influenza Treatment
Brief: Fusen Pharmaceutical Says Investors To Contribute RMB300 Mln For 34% Stake Subscription Of Henan Fusen Pharmaceutical
Brief: Fusen Pharmaceutical Says Piracetam Injection Approved For Marketing By NMPA